The French investigation into birth defects caused by the anti-epileptic medicine, sodium valproate, has taken another turn after the national regulatory agency, ANSM, was indicted for injury and manslaughter through negligence.
The indictment is part of a criminal investigation conducted by the Paris Court of Justice into why action was not taken sooner to communicate the risks of valproate
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?